Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies

  • Authors:
    • C Haas
    • V Schirrmacher
  • View Affiliations

  • Published online on: November 1, 1997     https://doi.org/10.3892/ijo.11.5.951
  • Pages: 951-957
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This report describes the generation of bispecific antibodies which bind with one arm to virus modified tumor cell vaccines and introduce with the other arm anti-murine CD28 T cell costimulatory molecules. This is an effective alternative to somatic gene therapy strategies using genes coding for ligands of CD28 such as CD80 (B7-1) or CD86 (B7-2). While these B7 molecules interact not only with CD28 but also with CLTA-4, thereby generating a negative signal, agonistic anti CD28 antibodies only bind to CD28 and therefore deliver only positive costimulatory signals. The new bispecific antibody (bsAb) HN x CD28 allows the introduction of anti-CD28 antibodies into the tumor cell vaccine ATV-NDV, an autologous tumor cell vaccine already modified by infection with Newcastle Disease Virus (NDV). The bsAb HN x CD28 attaches with its anti-HN binding site to the NDV derived hemagglutinin-neuraminidase (HN) molecule which serves as a common foreign anchoring molecule in the vaccine. NDV infected tumor cells which were further modified with HN x CD28 on their cell surface (bs-vaccine), showed increased T cell stimulatory capacity in vitro. This was revealed by augmented proliferation as well as augmented CTL activity. When syngeneic mice were injected with aggressive murine ESb lymphoma cells which were infected with NDV and further modified with the bsAb HN x CD28, delayed tumor development and prolonged survival was observed in comparison to respective controls.

Related Articles

Journal Cover

November 1997
Volume 11 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Haas C and Haas C: Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies. Int J Oncol 11: 951-957, 1997
APA
Haas, C., & Haas, C. (1997). Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies. International Journal of Oncology, 11, 951-957. https://doi.org/10.3892/ijo.11.5.951
MLA
Haas, C., Schirrmacher, V."Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies". International Journal of Oncology 11.5 (1997): 951-957.
Chicago
Haas, C., Schirrmacher, V."Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies". International Journal of Oncology 11, no. 5 (1997): 951-957. https://doi.org/10.3892/ijo.11.5.951